3Higgins GS,McLaren DB,Kerr GR,et al.Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy[J].Int J Radiat Oncol Biol Phys,2006,65(4):982.
4Oh WK.The evolving role of estrogen therapy in prostate cancer[J].Clin Prostate Cancer,2002,1(2):81-89.
5Labrie F,Be1anger A,Luu-The V,et al.Gonadotropin-releasing hormone agonists in the treatment of prostate cancer[J].Endoer Rev,2005,26(3):361-379.
6Yri OE,Bjoro T,Fossa SD.Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer[J].Eur Urol,2006,49(1):54-58.
7Weston P,Persson BE.Re:Weckermann D,Harzmann R.Hormone therapy in prostate cancer:LHRH antagonists versus LHRH analogues[J].Eur Urol,2004,46(3):279-284.
8AKaza H,Hinotsu S,Usami M,et al.Combined androgen blockade with bicalutamide for advanced prostate cancer:long-term follow-up of a phase 3,double-blind,randomized study for survival[J].Cancer,2009,115(15):3437-3445.
9Schellhammer PF,Davis JW.An evaluation of bicalutamide in the treatment of prostate cancerl[J].Clin Prostate Cancer,2004,2(4):213-219.
10Geller J,Albert J.Comparison of prostatic cancer tissue dihydrotestoster one level sat the time of rdaple following orchieetomyo restrogen therapy[J].J Urol,1984,132(4):693-696.
2Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55:74-108.
3Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006, 56:106-130.
4Michael PM, Bernard D, Kaill M, et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol, 2005, 174:1794-1797.
5Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. J Urol, 2004, 172 : 1822-1827.
6Benaim EA, Pace CM, Roehrbor CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urel, 2002, 42:12-17.
7Benaim EA, Pace CM, Lam PM, et al. Nadir PSA as a progression to androgeindependent prostate cancer. Urology, 2002, 59:73-77.
8Siddall JK, Hetherington JW, Cooper EH, et al. Biochemical monitoring of carcinoma of prostate treated with an LRH analogue (Zoladex). Br J Urol, 1986, 58:676-679.
9Mulders PF, Fernandez del MP, Theeuwes AG, et al. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol, 1992, 21:2-7.
10Darer A,Soret JY, Coblentz Y, et al. The usefulness of prostate- specific antigen and prostatic acid phosphatase in clinical practice. Am J Clin Oncol, suppl, 1988, 11 :S53-S57.
5Jacobs JJ, Snackey C, GeldofAA, et al. Inefficacy of th- erapeutic cancer vaccines and proposed improvements, ca- sus of prostate cancer[J]. Anticancer Res, 2014,34 ( 6 ) : 2 689.
6Tsao CK, Cutting E, Martin J, et al. The role of cabazita- xel in the treatment of metastatic castration-resistant pros- tate cancer[J]. Ther A dv Urol, 2 014,6 ( 3 ) : 9 7.
7Omlin A, Pezaro C, Gillessen SS.Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy[J]. Ther Adv Urol, 2014,6 ( 1 ) : 3.
